Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
6.74
+0.33 (5.23%)
At close: Mar 9, 2026, 4:00 PM EDT
6.54
-0.20 (-2.90%)
After-hours: Mar 9, 2026, 7:18 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
6.72M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| XTL Biopharmaceuticals | 968.00K |
| Can-Fite BioPharma | 560.00K |
| Aprea Therapeutics | 488.24K |
| Creative Medical Technology Holdings | 6.00K |
APVO News
- 4 weeks ago - Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Accesswire
- 2 months ago - Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Accesswire
- 2 months ago - Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Accesswire
- 3 months ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 4 months ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 5 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 6 months ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire